Ahead of Bristol Myers (BMY) Q3 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 10/27/25
Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus ErythematosusBusiness Wire • 10/27/25
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers SquibbAccesswire • 10/27/25
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025Business Wire • 10/25/25
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?Zacks Investment Research • 10/24/25
Buy 9 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 October Dividend DogsSeeking Alpha • 10/24/25
These low-risk stocks could be a profitable answer to this volatile earnings seasonMarket Watch • 10/23/25
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025PRNewsWire • 10/17/25
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend YieldsBenzinga • 10/15/25
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?Zacks Investment Research • 10/13/25
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor TypesBusiness Wire • 10/13/25